JCI - Citations to Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

Citations to this article

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

Heng Lin, … , Ilona Kryczek, Weiping Zou

Heng Lin, … , Ilona Kryczek, Weiping Zou

Published April 2, 2018
Citation Information: J Clin Invest. 2018;128(4):1708-1708. https://doi.org/10.1172/JCI120803.

View: Text | PDF | Amended Article

Total citations by year

Year:	2025	2024	2023	2022	2021	2020	2019	2018	Total
Citations:	4	14	14	14	18	20	7	6	97

Citation information

Citations to this article (97)

Title and authors	Publication	Year
Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements. Wang Y, Zhu N, Liu J, Chen F, Song Y, Ma Y, Yang Z, Wang D	Journal of translational medicine	2025
GPX4 knockdown suppresses M2 macrophage polarization in gastric cancer by modulating kynurenine metabolism. Xu J, Weng C, Zhang Y, Zhao Q, Chen J, Pan S, Wang Y, Zhang R, Wang Y, Zhu W, Cao M, Zu D, Zhang S, Xu Z, Hu C, Cheng X	Theranostics	2025
HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy Spadotto V, Ripamonti C, Ghiroldi A, Galbiati E, Pozzi P, Noberini R, Bonaldi T, Steinkühler C, Fossati G	Frontiers in Immunology	2025
Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review Wang Y, Ma C, Li X, Yang F, Wang N, Ji G, Liu Q, Zhu H, Xu S, Li H	Journal of Translational Medicine	2025
PD-L1 is an IFNγ-independent maturation marker on tumor-associated macrophages and associates with good clinical outcome in human breast cancer Lei Wang, Weihua Guo, Jiangnan Yu, Zhikun Guo, Jiayi Tan, Diana Simons, Ke Hu, Xinyu Liu, Qian Zhou, Yizi Zheng, Colt Egelston, John Yim, James Waisman, Peter Lee	Cell reports. Medicine	2024
Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma. Kim J, Kim TJ, Chae S, Ha H, Park Y, Park S, Yoon CJ, Lim SA, Lee H, Kim J, Kim J, Im K, Lee K, Kim J, Kim D, Lee E, Shin MH, Park SI, Rhee I, Jung K, Lee J, Lee KH, Hwang D, Lee KM	Molecular Cancer	2024
In vivo CRISPR screens identify Mga as an immunotherapy target in triple-negative breast cancer Xu Feng, Chang Yang, Yuanjian Huang, Dan Su, Chao Wang, Lori Wilson, Ling Yin, Mengfan Tang, Siting Li, Zhen Chen, Dandan Zhu, Shimin Wang, Shengzhe Zhang, Jie Zhang, Huimin Zhang, Litong Nie, Min Huang, Jae-Il Park, Traver Hart, Dadi Jiang, Kuirong Jiang, Junjie Chen	Proceedings of the National Academy of Sciences of the United States of America	2024
A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions Enzler T, Shi J, McGue J, Griffith BD, Sun L, Sahai V, Nathan H, Frankel TL	International journal of molecular sciences	2024
Macrophage: Hidden Criminal in Therapy Resistance Ding Y, Cao Q, Yang W, Xu J, Xiao P	Journal of Innate Immunity	2024
An AI-based approach for modeling the synergy between radiotherapy and immunotherapy. Peng H, Moore C, Zhang Y, Saha D, Jiang S, Timmerman R	Scientific Reports	2024
PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages Pitter MR, Kryczek I, Zhang H, Nagarsheth N, Xia H, Wu Z, Tian Y, Okla K, Liao P, Wang W, Zhou J, Li G, Lin H, Vatan L, Grove S, Wei S, Li Y, Zou W	Cell Reports	2024
Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors Lucà S, Accardo M, Campione S, Franco R		2024
From foes to friends: rethinking the role of lymph nodes in prostate cancer. Gupta R, Das CK, Nair SS, Pedraza-Bermeo AM, Zahalka AH, Kyprianou N, Bhardwaj N, Tewari AK	Nature Reviews Urology	2024
中医药调控肿瘤相关巨噬细胞防治肺癌转移的基础研究进展 LIU S, LI J, QUE Z, YU P, TIAN J	Chinese Journal of Lung Cancer	2024
Fusobacterium nucleatum: a novel regulator of antitumor immune checkpoint blockade therapy in colorectal cancer. Luo M, Li Q, Gu Q, Zhang C	American journal of cancer research	2024
Ferroptosis contributes to immunosuppression. He N, Yuan D, Luo M, Xu Q, Wen Z, Wang Z, Zhao J, Liu Y	Frontiers of medicine	2024
Understanding the PULSAR effect in combined radiotherapy and immunotherapy using transformer-based attention mechanisms Peng H, Moore C, Saha D, Jiang S, Timmerman R	Frontiers in Oncology	2024
Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC Arleo A, Montagner A, Giovannini C, Suzzi F, Piscaglia F, Gramantieri L	Biomolecules	2024
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer Zhou K, Li S, Zhao Y, Cheng K	Frontiers in immunology	2023
Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond Zhao Y, Du J, Shen X	Frontiers in immunology	2023
Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Zhang Y, Song Q, Cassady K, Lee M, Tang H, Zheng M, Wang B, Schones DE, Fu YX, Riggs AD, Martin PJ, Feng R, Zeng D	Proceedings of the National Academy of Sciences	2023
Tumor Cell-derived Extracellular Vesicles in Modulating Phenotypes and Immune Functions of Macrophages: Mechanisms and Therapeutic Applications Tian JW, Zhang HJ, Li SY, Guo YL, Chen G, Yu ZL	Journal of Cancer	2023
Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy Xu S, Wang C, Yang L, Wu J, Li M, Xiao P, Xu Z, Xu Y, Wang K	Frontiers in immunology	2023
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, Wei S, Grove S, Vatan L, Nelson R, Schaefer G, Allen SG, Sankar K, Fecher LA, Mendiratta-Lala M, Frankel TL, Qin A, Waninger JJ, Tezel A, Alva A, Lao CD, Ramnath N, Cieslik M, Harms PW, Green MD, Chinnaiyan AM, Zou W	Cancer Cell	2023
Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers Sulaiman R, De P, Aske JC, Lin X, Dale A, Koirala N, Gaster K, Espaillat LR, Starks D, Dey N	International journal of molecular sciences	2023
Immunometabolism at the crossroads of obesity and cancer—a Keystone Symposia report Cable J, Rathmell JC, Pearce EL, Ho PC, Haigis MC, Mamedov MR, Wu MJ, Kaech SM, Lynch L, Febbraio MA, Bapat SP, Hong HS, Zou W, Belkaid Y, Sullivan ZA, Keller A, Wculek SK, Green DR, Postic C, Amit I, Benitah SA, Jones RG, Reina-Campos M, Torres SV, Beyaz S, Brennan D, O\u2019Neill LA, Perry RJ, Brenner D	Annals of the New York Academy of Sciences	2023
A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon Yi J, Lin P, Li Q, Zhang A, Kong X		2023
Complementary CRISPR screen highlights the contrasting role of membrane-bound and soluble ICAM-1 in regulating antigen-specific tumor cell killing by cytotoxic T cells Herzfeldt AK, Gamez MP, Martin E, Boryn LM, Baskaran P, Huber HJ, Schuler M, Park JE, Swee LK	eLife	2023
A Comparative Study of Antitumor Immunity Induced by Radiofrequency Microwave and Cryoablation in Hepatocellular Carcinoma. Zhang K, Liu M, Cong L, He X, Xu Y, Wang Q, Li C	Applied Biochemistry and Biotechnology	2023
Research Progress on the Mechanism of Anti-Tumor Immune Response Induced by TTFields Lan Y, Zhang S, Pan Y, Wang M, Chen G	Cancers	2023
Unique characteristics of the tumor immune microenvironment in young patients with metastatic colorectal cancer. Griffith BD, Lazarus J, McGue J, Krishnan S, D'Angelica MI, Shia J, Dobrosotskaya I, Shi J, Edwards J, Rao A, Frankel TL	Frontiers in immunology	2023
The role of the MDM2/p53 axis in antitumor immune responses Brummer T, Zeiser R	Blood	2023
Inhibiting MNK kinases promotes macrophage immunosuppressive phenotype to limit CD8+ T cell anti-tumor immunity Thao N.D. Pham, Christina Spaulding, Mario Shields, Anastasia E Metropulos, Dhavan N. Shah, Mahmoud Khalafalla, Daniel R Principe, David Bentrem, Hidayatullah G. Munshi	JCI Insight	2022
PD-1/PD-L1 blockade is a potent adjuvant for treating Staphylococcus aureus osteomyelitis in mice Kaiqun Li, Yuhui Chen, Yihuang Lin, Te Chen, Jianwen Su, Xiaohu Wu, Caiyu Cheng, Yutian Wang, Bin Yu, Xianrong Zhang	Molecular Therapy	2022
Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression B Hwang, L Tsao, C Acharya, T Trotter, P Agarwal, J Wei, T Wang, X Yang, G Lei, T Osada, H Lyerly, M Morse, Z Hartman	Journal for ImmunoTherapy of Cancer	2022
Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy A Adeshakin, F Adeshakin, D Yan, X Wan	Frontiers in immunology	2022
Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy C Lee, D Atibalentja, L Yao, J Park, S Kuruvilla, D Felsher	Nanotheranostics	2022
TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy De Ridder K, Locy H, Piccioni E, Zuazo MI, Awad RM, Verhulst S, Van Bulck M, De Vlaeminck Y, Lecocq Q, Reijmen E, De Mey W, De Beck L, Ertveldt T, Pintelon I, Timmermans JP, Escors D, Keyaerts M, Breckpot K, Goyvaerts C	Frontiers in immunology	2022
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. Zhao X, Bao Y, Meng B, Xu Z, Li S, Wang X, Hou R, Ma W, Liu D, Zheng J, Shi M	Frontiers in immunology	2022
Development of an exosome-related and immune microenvironment prognostic signature in colon adenocarcinoma Cui G, Wang C, Liu J, Shon K, Gu R, Chang C, Ren L, Wei F, Sun Z	Frontiers in Genetics	2022
Clinical implications of T cell exhaustion for cancer immunotherapy. Chow A, Perica K, Klebanoff CA, Wolchok JD	Nature reviews. Clinical oncology	2022
Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience F Sun, D Wang, A Liu, T Wang, D Zhang, H Yao, K Sun, Z Zhou, G Lu, J Wu	Frontiers in pharmacology	2022
Efficacy, Safety, and Impact on Patient Survival of PDL1/PD-1 Inhibitors versus FOLFIRINOX Regimens for Advanced Pancreatic Cancer L Zhou, Z Wu, C Jiang, S Dai, M Tang	Computational and mathematical methods in medicine	2022
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy Zhang Y, Gabere M, Taylor MA, Simoes CC, Dumbauld C, Barro O, Tesfay MZ, Graham AL, Ferdous KU, Savenka AV, Chamcheu JC, Washam CL, Alkam D, Gies A, Byrum SD, Conti M, Post SR, Kelly T, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM	Frontiers in Oncology	2022
Editorial: Application of artificial intelligence in improving immunotherapeutic efficacy. Li J, Zhang Y, Liu Z, Han X	Frontiers in pharmacology	2022
Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma Chen S, Zhang L, Lin H, Liang Y, Wang Y	Biomolecules	2022
Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages M Reis-Sobreiro, AT da Mota, C Jardim, K Serre	Cells	2021
The role of macrophages in anti-tumor immune responses: pathological significance and potential as therapeutic targets H Tsukamoto, Y Komohara, H Oshiumi	Human Cell	2021
EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses DR Menon, Y Li, T Yamauchi, DG Osborne, PK Vaddi, MF Wempe, Z Zhai, M Fujita	Pharmaceuticals (Basel, Switzerland)	2021
USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1 J Pan, Y Qiao, C Chen, H Zang, X Zhang, F Qi, C Chang, F Yang, M Sun, S Lin, Q Tang, L Li, M Wang, M Wu, Y Liu, C Lai, J Chen, G Chen	Cell Death and Disease	2021
In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis S Kim, SA Kim, GH Nam, Y Hong, GB Kim, Y Choi, S Lee, Y Cho, M Kwon, C Jeong, S Kim, IS Kim	Journal for ImmunoTherapy of Cancer	2021
Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding H Jin, V D'Urso, B Neuteboom, SD McKenna, R Schweickhardt, AW Gross, YF Nanfack, A Paoletti, C Carter, L Toleikis, M Fluck, J Scheuenpflug, T Cai	OncoImmunology	2021
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade C Moore, CC Hsu, WM Chen, BP Chen, C Han, M Story, T Aguilera, LM Pop, R Hannan, YX Fu, D Saha, R Timmerman	International journal of radiation oncology, biology, physics	2021
Tumor-Derived Small Extracellular Vesicles Induce Pro-Inflammatory Cytokine Expression and PD-L1 Regulation in M0 Macrophages via IL-6/STAT3 and TLR4 Signaling Pathways M Pucci, S Raimondo, O Urzì, M Moschetti, MA Bella, A Conigliaro, N Caccamo, MP Manna, S Fontana, R Alessandro	International journal of molecular sciences	2021
LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy G Li, I Kryczek, J Nam, X Li, S Li, J Li, S Wei, S Grove, L Vatan, J Zhou, W Du, H Lin, T Wang, C Subramanian, JJ Moon, M Cieslik, M Cohen, W Zou	Nature Cell Biology	2021
Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics Z Ye, X Ai, L Zhao, F Fei, P Wang, S Zhou	Oncogene	2021
Programmable Unlocking Nano‐Matryoshka‐CRISPR Precisely Reverses Immunosuppression to Unleash Cascade Amplified Adaptive Immune Response J Yang, Z Li, M Shen, Y Wang, L Wang, J Li, W Yang, J Li, H Li, X Wang, Q Wu, C Gong	Advanced Science	2021
Identification of chemical compounds regulating PD‐L1 by introducing HiBiT‐tagged cells Y Uchida, T Matsushima, R Kurimoto, T Chiba, Y Inutani, H Asahara	FEBS Letters	2021
Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner K Zhao, Q Zhang, SA Flanagan, X Lang, L Jiang, LA Parsels, JD Parsels, W Zou, TS Lawrence, R Buisson, MD Green, MA Morgan	Molecular cancer research : MCR	2021
Intestinal Bacteria Encapsulated by Biomaterials Enhance Immunotherapy Y Liu, Z Li, Y Wu, X Jing, L Li, X Fang	Frontiers in immunology	2021
Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion X Wu, YS Cheng, M Matthen, A Yoon, GK Schwartz, S Bala, AM Taylor, F Momen-Heravi	Journal of Experimental & Clinical Cancer Research	2021
The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer C Zhai, X Zhang, L Ren, L You, Q Pan, H Pan, W Han	Frontiers in Oncology	2021
Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer S Batman, K Matsuo, P Mhawech-Fauceglia, E Munro, M Weisenberger, A Allen, S Joshi, H Machida, S Matsuzaki, T Bozanovic, T Pejovic	Cancers	2021
Identification of JAK2 and FOXM1 expression as novel candidate biomarkers for predicting the benefit of immunotherapy in lung squamous cell carcinoma S Zhang, S Liu, , J Liu, W Wu	Annals of translational medicine	2021
Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice W Qin, J Zou, Y Huang, C Liu, Y Kang, H Han, Y Tang, L Li, B Liu, W Zhao, X Yuan	OncoImmunology	2020
Diversity, Mechanisms, and Significance of Macrophage Plasticity M Locati, G Curtale, A Mantovani	Annual review of pathology	2020
Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy A Nguyen, A Ramesh, S Kumar, D Nandi, A Brouillard, A Wells, L Pobezinsky, B Osborne, AA Kulkarni	Science Advances	2020
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade E Peranzoni, V Ingangi, E Masetto, L Pinton, I Marigo	Frontiers in immunology	2020
Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade L Wang, Y Gao, G Zhang, D Li, Z Wang, J Zhang, LC Hermida, L He, Z Wang, J Si, S Geng, R Ai, F Ning, C Cheng, H Deng, DS Dimitrov, Y Sun, Y Huang, D Wang, X Hu, Z Wei, W Wang, X Liao	Science Translational Medicine	2020
The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy CM Neophytou, C Pierides, MI Christodoulou, P Costeas, TC Kyriakou, P Papageorgis	Frontiers in Oncology	2020
Biomarkers of immunotherapy in non‑small cell lung cancer (Review) L Wang, Y Hu, S Wang, J Shen, X Wang	Oncology Letters	2020
Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies K Zhou, S Guo, F Li, Q Sun, G Liang	Frontiers in Cell and Developmental Biology	2020
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer E Crespo-Rodriguez, K Bergerhoff, G Bozhanova, S Foo, EC Patin, H Whittock, R Buus, S Haider, G Muirhead, K Thway, K Newbold, RS Coffin, RG Vile, D Kim, M McLaughlin, AA Melcher, KJ Harrington, M Pedersen	Journal for ImmunoTherapy of Cancer	2020
Targeting PD-L1 in non-small cell lung cancer using CAR T cells M Liu, X Wang, W Li, X Yu, P Flores-Villanueva, ZY Xu-Monette, L Li, M Zhang, KH Young, X Ma, Y Li	Oncogenesis	2020
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes F Dammeijer, M van Gulijk, EE Mulder, M Lukkes, L Klaase, T van den Bosch, M van Nimwegen, SP Lau, K Latupeirissa, S Schetters, Y van Kooyk, L Boon, A Moyaart, YM Mueller, PD Katsikis, AM Eggermont, H Vroman, R Stadhouders, RW Hendriks, J von der Thüsen, DJ Grünhagen, C Verhoef, T van Hall, JG Aerts	Cancer Cell	2020
Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model M Kocikowski, K Dziubek, M Parys	Cancers	2020
Targeting the PD-1/PD-L1 Axis in Human Vitiligo M Willemsen, CJ Melief, MW Bekkenk, RM Luiten	Frontiers in immunology	2020
Prognostic and Clinical Value of Interleukin 6 and CD45 + CD14 + Inflammatory Cells with PD-L1 + /PD-L2 + Expression in Patients with Different Manifestation of Ovarian Cancer I Wertel, D Suszczyk, A Pawłowska, M Bilska, A Chudzik, W Skiba, R Paduch, J Kotarski	Journal of Immunology Research	2020
Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma J Han, X Xu, Z Liu, Z Li, Y Wu, D Zuo	International Immunopharmacology	2020
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors AB Zaslavsky, MP Adams, X Cao, T., JE Choi, J Stangl-Kremser, S Patel, A Putelo, SK Lee, S Nallandhighal, A Kasputis, A Alva, M Lew, A Qin, R Mehra, TM Morgan, SS Salami, Z Reichert, A Udager, W Zou, GS Palapattu	Scientific Reports	2020
Monocyte-Derived Cells in Tissue-Resident Memory T Cell Formation KL Chu, NV Batista, M Girard, TH Watts	Journal of immunology (Baltimore, Md. : 1950)	2020
Prognostic and Clinical Value of Interleukin 6 and CD45 + CD14 + Inflammatory Cells with PD-L1 + /PD-L2 + Expression in Patients with Different Manifestation of Ovarian Cancer I Wertel, D Suszczyk, A Pawłowska, M Bilska, A Chudzik, W Skiba, R Paduch, J Kotarski	Journal of Immunology Research	2020
Inhibition of Lnc-OC1 Induced Cell Apoptosis and Decreased Cell Viability by Releasing miR-34a and Inhibiting PD-L1 in Endometrial Carcinoma Y Liu, Y Chang, Y Cai	Reproductive sciences (Thousand Oaks, Calif.)	2020
The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma M Schonfeld, J Zhao, A Komatz, SA Weinman, I Tikhanovich	The Journal of biological chemistry	2020
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment DD Fang, Q Tang, Y Kong, Q Wang, J Gu, X Fang, P Zou, T Rong, J Wang, D Yang, Y Zhai	Journal for ImmunoTherapy of Cancer	2019
PD-1/PD-L1 blockade in paediatric cancers: What does the future hold? J Moreno-Vicente, SA Beers, JC Gray	Cancer Letters	2019
CD137L-DCs, Potent Immune-Stimulators—History, Characteristics, and Perspectives Q Zeng, Y Zhou, H Schwarz	Frontiers in immunology	2019
Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization NY Sun, YL Chen, WY Wu, HW Lin, YC Chiang, CF Chang, YJ Tai, HC Hsu, CA Chen, WZ Sun, WF Cheng	Cancers	2019
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways Y Zhao, CK Lee, CH Lin, RB Gassen, X Xu, Z Huang, C Xiao, C Bonorino, LF Lu, JD Bui, E Hui	Immunity	2019
Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors K Ma, Q Jin, M Wang, X Li, Y Zhang	Expert Review of Molecular Diagnostics	2019
Current Status and Future Direction of Immune Checkpoint Inhibitors H Kagamu	Haigan	2019
The expanding constellation of immune checkpoints: a DNAMic control by CD155 Vincenzo Bronte	Journal of Clinical Investigation	2018
Integrin avb8 expressing tumor cells evade host immunity by regulating TGF-b activation in immune cells Naoki Takasaka, Robert I. Seed, Anthony Cormier, andrew bondesson, Jianlong Lou, Ahmed Elattma, Saburo Ito, Haruhiko Yanagisawa, Mitsuo Hashimoto, Royce Ma, Michelle Levine, Jean Publicover, Rashaun Potts, Jillian Jespersen, Melody Campbell, Fraser Conrad, James Marks, Yifan Cheng, Jody Baron, Stephen Nishimura	JCI Insight	2018
Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity Hui-Ming Chen, William van der Touw, Yuanshuo A Wang, Kyeongah Kang, Sunny Mai, Jilu Zhang, Dayanira Alsina-Beauchamp, J. Andrew Duty, Sathish Mungamuri, Bin Zhang, Thomas Moran, Richard A. Flavell, Stuart A Aaronson, Hong-Ming Hu, Hisashi Arase, Suresh Ramanathan, Raja Flores, ping-ying pan, Shu-Hsia Chen	Journal of Clinical Investigation	2018
Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing Z Li, W Song, M Rubinstein, D Liu	Journal of Hematology & Oncology	2018
Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics C McCloskey, G Rodriguez, K Galpin, B Vanderhyden	Cancers	2018
Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment ML Drakes, PJ Stiff	Cancers	2018

Advertisement